The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers

Antitumor immune responses against solid malignancies correlate with improved patient survival. We conducted a comprehensive investigation of immune responses in tumor and tumor-associated stroma in epithelioid malignant pleural mesothelioma with the goal of characterizing the tumor immune microenvironment and identifying prognostic immune markers. We investigated 8 types of tumor-infiltrating immune cells within the tumor nest and tumor-associated stroma, as well as tumor expression of 5 cytokine/chemokine receptors in 230 patients. According to univariate analyses, high densities of tumoral CD4- and CD20-expressing lymphocytes were associated with better outcomes. High expression of tumor interleukin-7 (IL-7) receptor was associated with worse outcomes. According to multivariate analyses, stage and tumoral CD20 detection were independently associated with survival. Analysis of single immune cell infiltration for CD163+ tumor-associated macrophages did not correlate with survival. However, analysis of immunologically relevant cell combinations identified that: (1) high CD163+ tumor-associated macrophages and low CD8+ lymphocyte infiltration had worse prognosis than other groups and (2) low CD163+ tumor associated macrophages and high CD20+ lymphocyte infiltration had better prognosis than other groups. Multivariate analyses demonstrated that CD163/CD8 and CD163/CD20 were independent prognostic factors of survival. With a recent increase in immunotherapy investigations and clinical trials for malignant pleural mesothelioma patients, our observations that CD20+ B lymphocytes and tumor-associated macrophages are prognostic markers provide important information about the tumor microenvironment of malignant pleural mesothelioma.

[1]  P. Greenberg,et al.  The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. , 1990, Science.

[2]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.

[3]  P. Stattin,et al.  Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. , 2000, International journal of oncology.

[4]  M Mazumdar,et al.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. , 2000, Statistics in medicine.

[5]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[6]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[7]  S. Grupp,et al.  RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. , 2004, Blood.

[8]  Li Zhu,et al.  Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells1 , 2005, The Journal of Immunology.

[9]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[10]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[11]  G. Watkins,et al.  Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo , 2005, The British journal of surgery.

[12]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[13]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[14]  K. Rosenzweig,et al.  Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Cindy B. Yeoh,et al.  Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  R. Tisch,et al.  Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice , 2007, Proceedings of the National Academy of Sciences.

[17]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[18]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[19]  M. Tsao,et al.  Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. , 2008, The Journal of thoracic and cardiovascular surgery.

[20]  W. Leonard,et al.  New insights into the regulation of T cells by γc family cytokines , 2009, Nature Reviews Immunology.

[21]  E. Wang,et al.  Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. , 2009, European journal of cancer.

[22]  C. Obasaju,et al.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Yoshizawa,et al.  Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[24]  Dongxia Gao,et al.  Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors , 2009, PloS one.

[25]  C. Palumbo,et al.  Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. , 2009, International journal of oncology.

[26]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[27]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[28]  M. Nishimura,et al.  CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection , 2010, Cancer Immunology, Immunotherapy.

[29]  M. Sadelain,et al.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma , 2011, Cancer Immunology, Immunotherapy.

[30]  M. Chatfield,et al.  Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  I. Ellis,et al.  The prognostic significance of B lymphocytes in invasive carcinoma of the breast , 2012, Breast Cancer Research and Treatment.

[33]  C. Sima,et al.  Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  C. Sima,et al.  Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients , 2011, Cancer Immunology, Immunotherapy.

[35]  C. Sima,et al.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma , 2012, Modern Pathology.

[36]  Prasad S Adusumilli,et al.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma , 2012, Modern Pathology.

[37]  V. Brower.  Macrophages: cancer therapy's double-edged sword. , 2012, Journal of the National Cancer Institute.

[38]  C. Sima,et al.  Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients , 2012, Clinical Cancer Research.

[39]  S. Steinberg,et al.  Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression , 2013, Science Translational Medicine.

[40]  J. Nitadori,et al.  Prognostic value of the immune microenvironment in lung adenocarcinoma , 2013, Oncoimmunology.

[41]  Yu Shen,et al.  Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. , 2013, Experimental cell research.

[42]  D. Lobo,et al.  The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays , 2013, BMC Cancer.

[43]  C. Sima,et al.  Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[44]  C. Sima,et al.  Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Sadelain,et al.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.